Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 10, 2016
Event: Entry into a Material Definitive Agreement (Collaboration, Option and License Agreement) with Regeneron Pharmaceuticals, Inc.
Key Financial Metrics and Deal Terms
This filing details a strategic collaboration rather than standard periodic financial results. Key financial terms of the agreement include:
- Upfront Payment: $10 million payable by Regeneron upon exercise of the Option.
- Development Milestones: Up to $145 million per Licensed Product upon achievement of specified development and regulatory milestones.
- Commercial Milestones: $100 million per Licensed Product upon first commercial sale.
- Sales Milestones: Up to $50 million based on specified sales milestones for all Licensed Products.
- Royalties: Tiered, escalating royalties ranging from high-single digit to low-to-mid teen percentage of net sales.
- Cost Reimbursement Cap: Ocular Therapeutix is obligated to reimburse Regeneron for certain development costs up to a cap of $25 million (potentially increaseable by $5 million).
Note: The filing does not provide current revenue, profit, cash flow, or debt figures for the Company.
Material Changes and Agreement Scope
The Company entered into a joint research program to develop a sustained-release formulation of aflibercept (a large molecule VEGF-targeting compound) using Ocular Therapeutix's hydrogel depot technology. The agreement is limited to ophthalmic diseases or conditions delivered via local administration to or around the eye. It explicitly excludes small molecule drugs (including tyrosine kinase inhibitors) and large molecule drugs not targeting specified VEGF proteins.
Regeneron holds an exclusive option for 12 months after receiving a product candidate, followed by a six-month non-exclusive period. Upon exercise, Regeneron assumes responsibility for further development and commercialization funding after the initial clinical trial phase.
Outlook, Risks, and Contingencies
- Expiration: If the Option is not exercised, the agreement expires. If exercised, it expires on a product-by-product and country-by-country basis after the later of 10 years from first commercial sale or patent expiration.
- Termination: Regeneron may terminate the agreement at any time after exercising the Option with 60 days' prior written notice. Either party may terminate for uncured material breach.
- Post-Expiration Rights: Following expiration, Regeneron retains a fully paid-up, non-exclusive license to continue development and commercialization.
- Documentation: The full Collaboration Agreement is intended to be filed as an exhibit to the Form 10-Q for the period ending September 30, 2016.
Investor Verification Checklist
- Verify the exercise of the Option by Regeneron to confirm the $10 million payment and subsequent funding obligations.
- Review the upcoming Form 10-Q (Q3 2016) for the full text of the Collaboration Agreement and specific milestone definitions.
- Monitor the joint research program progress toward delivering a product candidate suitable for clinical development.
- Assess the impact of the $25 million cost reimbursement cap on the Company's cash flow requirements.
- Confirm the specific VEGF-targeting compounds covered under the agreement to ensure alignment with Regeneron's pipeline.